非小细胞肺癌患者中PIK3CA基因突变的临床特征和预后
| 作者: |
1郑晓彬,
1吴标,
1庄武,
1蒋侃,
1苗茜,
2许春伟
1 福建医科大学附属福建省肿瘤医院胸部肿瘤内科，福州 350014 2 福建医科大学附属福建省肿瘤医院病理科，福州 350014 |
| 通讯: |
吴标
Email: wubiao97@qq.com 许春伟 Email: xuchunweibbb@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2017.05.015 |
摘要
目的：探讨非小细胞肺癌PIK3CA基因突变的临床特征和预后。方法：回顾性分析16例PIK3CA基因突变的非小细胞肺癌临床特征，Kaplan-Meier法计算生存率，Log-rank法进行生存率显著性检验。结果：非小细胞肺癌中PIK3CA基因突变率3.09%(16/517)，中位总生存时间23.0个月，其中复合突变12例，中位总生存时间28.0个月，单纯突变4例，中位总生存时间21.0个月，两者差异无统计学意义(P=0.06)；伴随EGFR基因突变5例，中位总生存时间28.5个月，不伴随EGFR基因突变11例，中位总生存时间21个月(P=0.45)；伴随TP53基因突变4例，中位总生存时间30.6个月，不伴随TP53基因突变12例，中位总生存时间21.0个月(P=0.51)。结论：PIK3CA基因突变非小细胞肺癌临床特征上无特异性，但复合突变比单纯突变临床可能获益更多。
关键词：
非小细胞肺癌
PIK3CA
临床特征
预后
Clinical features and prognosis of non-small cell lung cancer harboring PIK3CA mutations
CorrespondingAuthor: WU Biao Email: wubiao97@qq.com
DOI: 10.3978/j.issn.2095-6959.2017.05.015
Abstract
Objective: To investigate clinical features and prognosis of non-small cell lung cancer harboring PIK3CA mutations. Methods: We retrospectively reviewed clinical features from 16 patients with NSCLC, and the survival rate was calculated by Kaplan-Meier method and log-rank test was used to compare the survival rates. Results: PIK3CA gene mutation rate was 3.09% (16/517) in non-small cell lung cancer, the median overall survival time was 23.0 months, including 12 cases compound mutation, the median overall survival time for 28 months, 4 cases simple mutation, the median overall survival time for 21.0 months, but there were no statistical differences (P=0.06), with EGFR mutations in 5 cases, the median overall survival time for 28.5 months, and without EGFR mutations in 11 cases, the median overall survival time for 21.0 months (P=0.45), with TP53 mutations in 4 cases, the median overall survival time for 30.6 months, and without TP53 mutations in 12 cases, the median overall survival time for 21.0 months(P=0.51). Conclusion: There is no specific in PIK3CA gene mutations non-small cell lung cancer. Patients with complex mutations may be more benefit from therapy than those with single mutations.